Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Maude, Shannon L., Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, et al. “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.” N Engl J Med 378, no. 5 (February 1, 2018): 439–48. https://doi.org/10.1056/NEJMoa1709866.

Full Text

Patel, Sachit A., Heather A. Allewelt, Jesse D. Troy, Paul L. Martin, Timothy A. Driscoll, Vinod K. Prasad, Joanne Kurtzberg, Kristin M. Page, and Suhag H. Parikh. “Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.” Biol Blood Marrow Transplant 23, no. 10 (October 2017): 1722–28. https://doi.org/10.1016/j.bbmt.2017.06.013.

Full Text

Wang, Hong, Man Huang, Ying Zhao, Jia-Qian Qi, Chun Chen, Ya-Qiong Tang, Hui-Ying Qiu, et al. “Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.” Biology of Blood and Marrow Transplantation 23, no. 10 (October 2017): 1678–84. https://doi.org/10.1016/j.bbmt.2017.06.010.

Full Text

Maude, S. L., S. A. Grupp, M. A. Pulsipher, S. Rives, G. D. Myers, M. R. Verneris, J. Buechner, et al. “ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL).” In Haematologica, 102:197–98. FERRATA STORTI FOUNDATION, 2017.

Scholars@Duke

Buechner, J., S. A. Grupp, S. L. Maude, M. Boyer, H. Bittencourt, T. W. Laetsch, P. Bader, et al. “GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS.” In Haematologica, 102:178–178. FERRATA STORTI FOUNDATION, 2017.

Scholars@Duke

Stafford, Lauren, Jesse D. Troy, Timothy A. Driscoll, Kristin Page, Suhag Parikh, Vinod K. Prasad, Joanne Kurtzberg, and Paul L. Martin. “Outcomes of Second Transplants for Patients with Hematological Malignancies Who Relapse after First Transplant: A Retrospective Analysis of a Single Institution Experience.” In Biology of Blood and Marrow Transplantation, 23:S152–S152, 2017.

Scholars@Duke

Parikh, Suhag, Joel Brochstein, Paul L. Martin, Mitchell E. Horwitz, Einat Galamidi, Iddo Peleg, Uri Goshen, et al. “Successful Engraftment of Umbilical Cord Blood (UCB) Cells after Co-Transplantation of Nicord (R) (Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and an Unmanipulated UCB Unit after Myeloablative Chemotherapy in Severe Sickle Cell Disease.” In Biology of Blood and Marrow Transplantation, 23:S150–51, 2017.

Scholars@Duke

Grupp, Stephan A., Theodore W. Laetsch, Jochen Buechner, Henrique Bittencourt, Shannon L. Maude, Michael R. Verneris, Gary D. Myers, et al. “Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).” In Blood, 128:221–221. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.221.221.

Full Text

Parikh, Suhag H., Joel Brochstein, Paul L. Martin, Mitchell E. Horwitz, Einat Galamidi, Iddo Peleg, Uri Goshen, et al. “Successful Engraftment of Donor Umbilical Cord Blood (UCB) Cells after Co-Transplantation of Nicord® (Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Pediatric Patients with Severe Sickle Cell Disease.” In Blood, 128:3651–3651. American Society of Hematology, 2016. https://doi.org/10.1182/blood.v128.22.3651.3651.

Full Text

Sayour, Elias J., Talal Mousallem, David Van Mater, Endi Wang, Paul Martin, Rebecca H. Buckley, and Raymond C. Barfield. “Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia.” Pediatr Blood Cancer 63, no. 10 (October 2016): 1856–59. https://doi.org/10.1002/pbc.26092.

Full Text

Pages